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Blastoid Variant Mantle Cell Lymphoma with Complex 
Karyotype Including 11q Duplication
11q Duplikasyonu İçeren Kompleks Karyotipe Sahip Bir Blastoid 
Varyant Mantle Hücreli Lenfoma
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Abstract:
We describe a case of blastoid mantle cell lymphoma with a complex karyotype. The blastoid variant is a rare type of 
non-Hodgkin lymphoma exhibiting an aggressive clinical course. Mantle cell lymphoma is a distinct entity of mature 
B-cell neoplasms genetically characterized by the presence of  t(11;14). In the present case, conventional analysis 
revealed structural abnormalities of chromosomes 2, 4, 6, 10, 13, and 19, along with 3 additional marker chromosomes. 
The derivative 1 chromosome determined in the case was a result of t(1p;11q). Our interesting finding was the 
presence of a different translocation between 11q and chromosome 1 in addition to t(11;14). Thus, the resulting 11q 
duplication was believed to additionally increase the enhanced expression of cyclin D1 gene, which is responsible 
in the pathogenesis of the disease. Fluorescence in situ hybridization method by the t(11;14) probe revealed clonal 
numerical abnormalities of chromosomes 11 and 14 in some cells. The detection of multiple abnormalities explains 
the bad prognosis in the present case. On the basis of our findings, we can easily conclude that results of cytogenetic 
analyses of similar mantle cell lymphoma patients would provide clues about new responsible gene regions and disease 
prognosis. In conclusion, it has been suggested that the presence of multiple chromosomal aberrations in addition to 
the specific t(11;14) may have a negative impact on clinical course and survival rate.
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Özet:
Kompleks karyotipe sahip bir blastoid mantle hücreli lenfoma olgusunu sunuyoruz. Blastoid alt tip, saldırgan bir klinik 
seyre sahip olup, ender görülen bir Hodgkin dışı lenfoma alt tipidir. Mantle hücreli lenfoma ise, özellikle t(11;14) 
varlığı ile diğer B hücreli neoplazmlardan ayırt edilmektedir. Sunulan olguda geleneksel kromozom analizi sonrası 
1, 2, 4, 6, 10, 13 ve 19. kromozomların yapısal anormalliklerine ek olarak 3 adet marker kromozom saptanmıştır. 
Hastamızda ayrıca, t(1p;11q) sonucunda oluşmuş türev 1. kromozom gözlenmiştir. Buradan hareketle, 11q bölgesinin, 
ilginç olarak t(11;14) haricinde 1. kromozom ile farklı bir translokasyona da katıldığını söyleyebiliriz. Bu nedenle 
ortaya çıkan 11q duplikasyonunun hastalığın oluşma sürecinden sorumlu tutulan siklin D1 geninin ifadelenmesini 
arttırdığı düşünülmektedir. Çalışma sırasında, floresan in situ melezleme yöntemi ile t(11;14) probu kullanılarak bazı 
hücrelerde klonal sayısal 11. ve 14. kromozom anormallikleri görüntülenmiştir. Çok sayıda kromozom bozukluğunun 
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Case Report 
saptanmış olması olgumuzun kötü klinik gidişini açıklamaktadır. Hastamıza ilişkin bulgularımız ışığında, aynı tanıya 
sahip hasta grubunda yapılacak sitogenetik inceleme sonuçlarının yeni sorumlu gen bölgeleri hakkında ipuçları 
vereceği rahatlıkla söylenebilir. Sonuç olarak, hastamızda t(11;14) varlığına ek olarak çoklu kromozom bozukluklarının 
bulunmasının, klinik gidiş ve tedavi yanıtı üzerine olumsuz bir etki gösterdiği açıktır.
Anahtar Sözcükler: Sitogenetik, Hodgkin Dışı Lenfoma, Diğer lenfoproliferatif hastalıklar, Diğer lösemiler
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Introduction
Mantle cell lymphoma (MCL) is a mature  B-cell 
neoplasm defined as a distinct entity in 1992 constituting 
4%-6% of all non-Hodgkin lymphomas [1]. The clinical 
course of MCL ranges from an indolent disease to a 
rapidly progressive malignancy, with poor prognosis and 
a median overall survival of about 3-5 years as reported 
in earlier studies [2,3]. The disease is typically advanced 
at diagnosis, with a leukemic component in 20%-30% 
of patients [1]. MCL is responsive to a great variety of 
initial therapies, but relatively short-term remissions are 
achieved with conventional strategies or with intensive 
treatment approaches [4]. The genetic hallmark of 
disease is the translocation t(11;14) (q13;q32) leading to 
aberrant expression of cyclin D1, which is not typically 
expressed in normal lymphocytes [1]. Many cases have 
additional cytogenetic abnormalities and often have a 
complex karyotype. Leukemic presentation of  MCL 
can cause diagnostic confusion with other CD5+ B-cell 
leukemias and the use of cytogenetic techniques, together 
with morphology and immunophenotype, is required to 
establish the correct diagnosis [5]. Here, we report the 
clinical correlation and prognostic impact of a panel of 
cytogenetic abnormalities detected in a case of a blastoid 
variant of MCL with a rare association of a complex 
translocation by fluorescence in situ hybridization (FISH) 
and conventional cytogenetic analysis.
Case Presentation
Clinical Progression
A 74-year-old female consulted with the Outpatient 
Clinic of the Gynecology and Obstetrics Department 
because of fatigue, abdominal pain, and B symptoms. 
Abdominal and thoracic computerized tomography revealed 
hepatosplenomegaly; paraaortic, mesenteric, and parailiac 
multiple enlarged lymph nodes; a mass lesion on the mid-
line in accordance with conglomerate lymphoid tissue at the 
periumblical localization; and mediastinal, hilar, and bilateral 
axillary and supraclavicular widespread lymphadenopathies. 
Total excision biopsy was performed on the left supraclavicular 
lymph nodes and this biopsy material revealed diffuse 
infiltrations and patched nodular configurations, along with 
atypical irregularly shaped lymphoid cells that showed diffuse 
and strong immunohistochemical staining with cyclin D1 and 
CD20. The patient entered our close follow-up program with 
the diagnosis of MCL. Bone marrow biopsy material showed 
infiltration by flow cytometry and pathologic examination. 
The patient’s Mantle Cell Lymphoma International 
Prognostic Index score was 11 (high risk). During the course 
of diagnosis, the patient had febrile neutropenia and diffuse 
pleural effusion accompanying pneumonia. The patient was 
followed in the intensive care  unit, with multiple antibiotic 
treatments againts pseudomonal, gram (+), fungal, and 
atypical agents in accordance with the febrile neutropenia 
protocol. At this time, an R-Hyper CVAD A-arm regimen 
containing cyclophosphamide, vincristine, doxorubicin, and 
dexamethasone alternating with a high-dose methotrexate 
and cytarabine + rituximab combination was started with 
modified doses. Active hematochezia started on the third 
day of chemotherapy, and in the following days, sepsis, 
disseminated intravascular coagulation, and multiple organ 
failure developed. On the sixth day of treatment, the patient 
died with the above-mentioned clinical picture despite all 
interventions.
Genetic Analyses
Conventional cytogenetic analysis was performed on 
induced cultures set up from bone marrow aspiration 
samples. Chromosomes were harvested after 72 and 120 
h of incubation following colcemid addition. Giemsa-
trypsin (GTG) banded chromosomes were analyzed and the 
composite karyotype was reported according to the 2009 
International System for Human Cytogenetic Nomenclature 
as 44x47, XX, der(1) t(1p;11q), der(2) t(2q;?) der(4) 
t(4q;11q), del(6q), der(10) t(10q;?), t(11;14) (q13;q32), 
der(13) t(13q;?), der(19) t(19p;?), +3mar[cp8]/46, XX[2] 
[6] (Figures 1 and 2).     
For FISH, metaphase spreads were hybridized with the 
LSI IGH/CCND1-XT DF probe (Vysis, Abbott Park, IL, USA) 
in order to investigate MCL-specific t(11;14) translocation. 
Additionally, numerical abnormalities of chromosomes 11 
and 14 were also observed.
Hybridization with the whole chromosome 11 probe 
(WCP 11, ID Labs, London, ON, Canada) supported our 
finding in the conventional karyotype, as we observed the 
chromosome 11 signal on chromosome 1, indicating a 
translocation between chromosomes 1 and 11 (Figure 3).
Discussion and Review of the Literature
Although MCL accounts for only 5% to 10% of all 
lymphoma diagnoses, it contributes disproportionately 
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to lymphoma deaths because of its often aggressive 
clinical course and lack of definitive curative therapy. 
MCL is a malignancy with distinct molecular genetics and 
pathological features. Peripheral blood involvement has 
been reported with variable frequency, but information on 
the natural history of patients presenting with leukemia is 
lacking [7]. For the present case, diagnosis was based on 
morphology, immunophenotype, presence of t(11;14), 
histology, and cyclin D1 expression. MCL usually consists of 
small to medium-sized lymphoid cells with irregular nuclear 
contours, somewhat dispersed chromatin, inconspicuous 
nucleoli, and scant cytoplasm [8]. According to the World 
Health Organization lymphoma classification, 4 cytologic 
variants of MCL can be defined, including the small cell 
variant, the marginal zone-like variant, the blastoid variant, 
and the pleomorphic variant [9]. The blastoid (approximately 
20% of all MCLs) and pleomorphic variants are considered 
to be associated with a poorer prognosis.
The patient presented with splenomegaly, abdominal 
and mediastinal lymphadenopathy, pleural effusion, and 
peripheral blood lymphoma cells. A bone marrow (BM) 
smear showed an increase in large, abnormal lymphoid cells 
with oval or round nuclei, distinct nucleoli, and basophilic 
cytoplasm with vacuolization. Flow cytometry analysis from 
peripheral blood and BM showed these cells to be positive 
for CD5, CD19, IgM/D, and CD20 and negative for CD10 
and CD23. Additionally, an immunohistochemical pattern 
positive for CD5, CD19, bcl-2, CD20, CD79a, and cyclin D1 
and negative for CD23 and CD30 was found in both lymph 
node and BM specimens. A blastoid variant of MCL was 
diagnosed from these results. According to the Ann Arbor 
staging system, the patient was accepted as stage IV and the 
performance status was grade 3-4 according to the Eastern 
Cooperative Oncology Group scale. 
The CCND1/IGH gene rearrangement is the most 
important factor in the diagnosis of MCL. The t(11;14) 
determines the ectopic and deregulated expression of cyclin 
D1, which is not typically expressed in normal lymphoid 
cells. A disease’s aggressive clinical behavior is related to 
its genetic and molecular pathogenesis, which integrates 
alterations in cell cycle regulation, DNA damage response 
mechanisms, and activation of cell survival pathways [10]. 
The patient died during first-line therapy with a rapid 
and bad course, in accordance with the aggressive properties 
of primary disease with a complex karyotype, along with the 
contribution of her advanced age and chemotherapeutic side 
effects. The presence of multiple chromosome abnormalities 
in addition to t(11;14) is well known to be associated 
with blastoid variants and poor prognoses in MCL [11]. 
The additional chromosomal abnormality determined in 
the present case as a result of conventional cytogenetic 
analysis was reported in previous studies in different cases 
Figure 1. Karyotype of the patient showing t(11;14) and 
other chromosomal abnormalities 300x200 mm (96x96 
DPI).
Figure 2. Karyotype including t(11;14) and other 
chromosomal abnormalities observed in the patient 374x275 
mm (96x96 DPI).
Figure 3. FISH result of the patient after hybridization 
with WCP 11 probe. Signals were observed on der(1) 
t(1p;11q), der(11) t(11;14), (der)14 t(11;14) and on normal 
chromosome 11 on a previously GTG banded metaphase 
364x270 mm (96x96 DPI).
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[12,13]. Espinet et al., in their study including 145 MCL 
cases, reported a total of 550 chromosomal changes (14 
numerical and 403 structural). Among these, the most 
common secondary abnormalities were loss of 1p, 13q, 
and 17p; changes in 10p; and gains in 3q [13]. Numerical 
abnormalities include trisomy 3, trisomy 12, monosomy 
8, monosomy 9, and loss of sex chromosomes (X Y). The 
most common secondary abnormality was 13q deletion in 
the classic variant of MCL. In the present case, conventional 
analysis revealed structural abnormalities of chromosomes 
2, 4, 6, 10, 13, and 19, along with additional 3 marker 
chromosomes. The derivative 1 chromosome determined 
in the case was as a result of t(1p;11q). Our interesting 
finding was the presence of a different translocation between 
11q and chromosome 1 in addition to t(11;14). Thus, the 
resulting 11q duplication was believed to additionally 
increase the enhanced expression of the cyclin D1 (CCND1) 
gene, which is responsible in the pathogenesis of the disease. 
We think that this finding increases the importance of the 
current case. Moreover, the interest of this case lies in the 
presence of these aberrant clones that are not very widely 
known or studied although their presence was pointed out 
many years ago. Tetraploid chromosome clones in blastoid 
MCL variants with chromosome 1 involvement were first 
reported by Ott et al., while recurrent losses at 1p (55%), 
8p (29%), 9q (29%), 11q (55%), 13q (42%), and 17p (32%) 
and gains at 3q (39%), 8q (26%), 15q (23%), and 18q 
(23%) were recently reported in aggressive MCL presenting 
genomic complexity and high proliferation index [14,15]. 
Previous studies have reported that, in similar situations, 
additional findings can be determined by the FISH method 
in addition to conventional cytogenetics and that t(11;14) 
alone is not sufficient for development of a malignant 
phenotype [12]. Thus, the use of the FISH method in 
addition to conventional cytogenetic analysis for diagnosis 
would be beneficial for the patient in terms of clinical follow-
up and treatment. In the present case, the FISH method by 
the t(11;14) probe revealed clonal numerical abnormalities 
of chromosomes 11 and 14 in some cells. Although the FISH 
method does not require metaphase spreads, determining 
signals on the same metaphases, especially following GTG 
banding, would contribute to the clarification of the disease 
pathogenesis. However, the success of hybridization in the 
FISH method performed following GTG banding is low. In 
the present case, we were not able to evaluate t(4q;11q) due 
to hybridization failure after GTG banding. 
In cases with more than 2 structural abnormalities, the 
clinical prognosis has been reported to be unfavorable. In 
the present case, multiple structural abnormalities were 
detected concurrently. Following the analysis of the 10 
metaphases examined, a complex karyotype showing clonal 
abnormalities was reported. The detection of multiple 
abnormalities explains the bad prognosis in the present 
case. Although the enhanced expression of the CCND1 gene 
alone is held responsible for the development of lymphoma, 
the additional influence of tumor suppressors like TP53 and 
RB1 and oncogenes like BCL2, CD4, and MYC play a role in 
the development of MCL [12]. On the basis of our findings 
in the current case, we can easily conclude that results of 
cytogenetic analyses of similar MCL patients would provide 
clues about new responsible gene regions and disease 
prognosis.
We did not have the opportunity to investigate the 
present case at the molecular level. However, we think that 
in cases representing a complex karyotype, imaging with 
contemporary molecular methods that enable detailed 
investigation of all chromosomes and related gene areas 
with a single hybridization of patient DNA, such as array 
CGH, would be advantageous in clarifying the mechanisms 
underlying disease pathogenesis.
In conclusion, it has been suggested that the presence of 
multiple chromosomal aberrations in addition to the specific 
t(11;14) may have a negative impact on clinical course and 
survival rate. Written informed consent was obtained from 
the patient’s family.
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